IL-10 polymorphisms and prostate cancer risk: a meta-analysis

Shao, Ningsheng; Xu, Bingying; Yy, Mi; Lx, Hua

doi:10.1038/pcan.2011.6

Cited by 30 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This single base pair substitution has been named both -819C/T and rs1800871. At this time, a series of seven molecular epidemiological studies and metaanalyses have investigated the association between the IL-10 -819C/T polymorphism and the susceptibility to different cancer types among different populations (Chen et al, 2010;Persson et al, 2011;Shao et al, 2011;Wei et al, 2011;Xue et al, 2012;Zou et al, 2011). However, the results from these studies are inconsistent.…”

Section: Introductionmentioning

confidence: 90%

The Interleukin 10 −819C/T Polymorphism and Cancer Risk: A HuGE Review and Meta-Analysis of 73 Studies Including 15,942 Cases and 22,336 Controls

Liu²,

Huang

et al. 2013

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

The aim of the present work was to perform a meta-analysis to evaluate the association between the interleukin 10 (IL-10) -819C/T (rs1800871) polymorphism and cancer risk. A total of 73 studies, including 15,942 cancer cases and 22,336 controls, were identified in this meta-analysis. The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the random-effects model. Overall, no significant association was identified between the IL-10 -819C/T polymorphism and cancer risk. In the subgroup analyses, the T allele and TT genotype were associated with a moderately reduced cancer risk in the Asian population (T allele vs. Individuals who were homozygous for the T allele (TT) were found to be associated with significantly reduced gastric cancer risk in the Asian population. The heterozygous variant (CT) and the dominant model (TT/CT vs. CC) were associated with an increased risk for cervical and ovarian cancer. However, the IL-10 -819C/T polymorphism was not significantly associated with breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, prostate cancer, lymphoma, or melanoma. The depressed cancer risk of the TT genotype occurred in the studies of hospital-based case-control studies and the studies recruited less than 500 subjects, but no statistically significant results were found in the stratified analyses using genotyping method. The results suggest that the IL-10 -819TT genotype may be a protective factor for cancer in Asians, especially gastric cancer. In contrast, the CT genotype and the dominant model could be risk factors for cervical and ovarian cancer. The importance of stratifying by ethnicity, cancer type, study design, and sample size needs to be standardized in future studies, together with considering the association between the IL-10 -819C/T polymorphism and cancer risk. Furthermore, the linkage of -819C/T with other polymorphisms of the IL-10 gene may help explain the variability in findings.

show abstract

Section: Introductionmentioning

confidence: 90%

The Interleukin 10 −819C/T Polymorphism and Cancer Risk: A HuGE Review and Meta-Analysis of 73 Studies Including 15,942 Cases and 22,336 Controls

Liu²,

Huang

et al. 2013

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

show abstract

“…[32][33][34] XRCC1, which is involved in the DNA repair, has been studied extensively about the relationship with different cancers, such as urothelial bladder cancer, 35 breast cancer, 36 PCa 25,37 and so on. Previous results of the studies on the relationship between XRCC1 polymorphisms and PCa risk were contradictory.…”

Section: Discussionmentioning

confidence: 99%

XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis

Wei

Zhou

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Epidemiological studies have evaluated the association between X-ray repair cross-complementing group 1 gene (XRCC1) Arg399Gln and Arg194Trp polymorphisms and risk of prostate cancer (PCa). However, the results from the published studies on the association between these two XRCC1 polymorphisms and PCa risk are conflicting. To derive a more precise estimation of association between the XRCC1 polymorphisms and risk of PCa, we performed a meta-analysis. A comprehensive search was conducted to identify all case-control studies of XRCC1 polymorphisms and PCa risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Overall, we found that both Arg399Gln and Arg194Trp polymorphisms were not significantly associated with PCa risk. However, in stratified analysis by ethnicity, we found that the Arg399Gln polymorphism was significantly associated with PCa risk in Asian population (Gln/Gln vs Arg/Arg: OR ¼ 1.46, 95% CI: 1.05-2.03, P ¼ 0.03; Gln/Gln vs Arg/ Gln þ Arg/Arg: OR ¼ 1.48, 95% CI: 1.12-1.95, P ¼ 0.01). In this meta-analysis, we found that both Arg399Gln and Arg194Trp polymorphisms were not related to overall PCa risk. However, in subgroup analysis we found a suggestion that XRCC1 399Gln allele might be a low-penetrent risk factor for PCa only in Asian men.

show abstract

“…Those individuals who had prostatitis for more than one year had an increased risk of prostate cancer (RR=1.50; 95% CI, 1.08-2.08) (5). The role of inflammation as a potential risk factor for prostate cancer (PCa) is indirectly supported by the finding that chronic NSAID intake is capable of decreasing the risk for PCa (6,7), and by the observations that polymorphisms in the gene coding the anti-inflammatory cytokine interleukin-10 (IL-10) are correlated to PCa aggressiveness as well as to progression to advanced stage PCa (8).…”

Section: Prostatitis: Definition Clinical Implications and Mechanistmentioning

confidence: 79%

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

et al. 2011

View full text Add to dashboard Cite

Abstract. Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characteri zed by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate; broad antibiotic but also biofilm-inhibiting properties; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.

show abstract

IL-10 polymorphisms and prostate cancer risk: a meta-analysis

Cited by 30 publications

References 40 publications

The Interleukin 10 −819C/T Polymorphism and Cancer Risk: A HuGE Review and Meta-Analysis of 73 Studies Including 15,942 Cases and 22,336 Controls

The Interleukin 10 −819C/T Polymorphism and Cancer Risk: A HuGE Review and Meta-Analysis of 73 Studies Including 15,942 Cases and 22,336 Controls

XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

Contact Info

Product

Resources

About